| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4826
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7004 |
| filingDate |
2010-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2013-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013508307-A |
| titleOfInvention |
A pharmaceutical composition for treating cancer comprising trypsinogen and / or chymotrypsinogen and an active agent selected from selenium compounds, vanilloid compounds and cytosolic glycolytic reducing agents. |
| abstract |
The present invention relates generally to pharmaceutical compositions comprising protease proenzymes and their use for cancer treatment. The pharmaceutical composition is directed to a composition comprising a protease proenzyme and an active agent, which can provide a multi-functional approach for cancer treatment. Said pharmaceutical composition is also used to promote cell-cell adhesion between tumor cells, to bring about proteolysis of tumor cells, or to promote cell death, differentiation or immune recognition of tumor cells or It includes first and second protease proenzymes capable of activating the vicinity thereof, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical composition is also directed to a composition comprising first and second active agents that are capable of inducing intercellular activity of tumor cells with each other. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7004665-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016516058-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7058604-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018533612-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017512828-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019507129-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019511525-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7359519-B2 |
| priorityDate |
2009-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |